Poor
Mostly Misaligned
Patient Risk:
Moderate
Summary
Only the two general boxed-warning risk statements were evaluated and found supported; the overall response content (as provided) does not demonstrate comprehensive, on-label coverage of the boxed warning and related required safety language (e.g., neuraxial timing/catheter removal and monitoring), nor does it address contraindications or other materially relevant label sections mentioned as not evaluated.
Category Scores
Accurate Statements
Premature discontinuation of ELIQUIS (in the absence of adequate alternative anticoagulation) increases the risk of thrombotic events.
Supported by label 5.1: “Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.”
Neuraxial anesthesia or spinal/epidural puncture in patients treated with antithrombotic agents (including ELIQUIS) can lead to an epidural or spinal hematoma that can result in long-term or permanent paralysis.
Supported by label 5.3: “When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed… at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.”
Unsupported Statements
Contradictions
Important Omissions
Neuraxial/anesthesia procedural management language: catheter removal timing (do not remove earlier than 24 hours after last ELIQUIS dose; next dose not earlier than 5 hours after removal), and if traumatic puncture occurs, delay administration for 48 hours, plus instruction to monitor frequently for neurological impairment.
Importance:
High
Explicit boxed warning framing/coverage confirmation (whether these statements are within boxed warning content and/or inclusion of the boxed-warning-specific required text context), since the provided response did not demonstrate comprehensive boxed-warning content coverage beyond the two general risk statements.
Importance:
Moderate
Converting/interruption dosing administration specifics referenced in label (e.g., interruption timing before/after surgery per 2.4; switching guidance per 2.5) were mentioned as not evaluated and not addressed in the response content provided.
Importance:
Moderate
Contraindications: no evaluation or inclusion of any contraindication information.
Importance:
High
Use in specific populations related to provided label excerpts (notably pediatric neuraxial catheter timing note in 5.3: lack of data; discontinue ELIQUIS and consider short acting parenteral anticoagulant).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response correctly captured two high-level risk statements but omitted multiple specific neuraxial procedural timing and monitoring instructions and did not evaluate contraindications or specific-population guidance present in the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Misaligned
Primary Issue
Incomplete on-label safety coverage: missing neuraxial/anesthesia management timing/monitoring and lack of evaluation of contraindications and certain population-specific label statements.
Suggested Improvement
Include the full on-label neuraxial guidance from 5.3 (catheter removal and next-dose timing, traumatic puncture delay, frequent neurological monitoring, and pediatric-specific note) and explicitly address contraindications and any relevant population-specific warnings where the label excerpt includes them.